This website is an international information resource intended for international healthcare professionals outside the United States of America (US) and the United Kingdom (UK) who are interested in information about Boehringer Ingelheim oncology.
While the Internet serves a global community, the pharmaceutical industry is subject to country-specific regulatory considerations. This means that compound status or the registration status and approved product labels of Afatinib or Nintedanib may not be the same in different countries.
Information about approved products on this website is derived from the Summary of Product Characteristics (SPC) for Afatinib and Nintedanib in the EU. It is not country-specific and may vary from the approved label in the country where you are located. Please refer to your local Prescribing Information for full details.
By clicking on the link below you are declaring and confirming that you are a healthcare professional outside the United States of America and the United Kingdom and have read and understood this disclaimer.
Recent talks from Boehringer Ingelheim standalone meetings
Boehringer Ingelheim convened its newest edition of Conversations in Oncology in Latin America on September 23-24, 2016 in Buenos Aires, Argentina. The 2016 meeting continues Boehringer Ingelheim’s tradition of highly interactive annual scientific meetings focused on the latest research and developments in oncology.
To view slides from the various presentation, simply click on your file of choice below.
Recent Advances in the Molecular Biology of Cancer Therapy
State of the Art: Recent Therapeutic Advances in Lung Cancer 2016
Treatment algorithm for EGFR-M+ NSCLC: Where do the 3rd Generation EGFR TKIs fit in?
Best Practices in Oncologic Pathology
Design of Clinical Trials with Molecularly Targeted Therapies
Targeting Angiogenesis in NSCLC
State of the Art in NSCLC: Anti-angiogenic Therapy for 2nd Line
State of the Art: Colorectal Cancer (CRC)
Roundtable discussion: NINTEDANIB in 2ND line for NSCLC
Immunotherapeutic Approaches in the Treatment of NSCLC
State of the Art: Management of Squamous Cell Carcinoma of the Head and Neck
Using this link will let you leave a website of Boehringer Ingelheim International GmbH (“BI”) or to a different domain under the control of BI. In the event that the linked site is not under the control of BI but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, BI shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites. This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by BI of the site.
Do you want to continue ?Continue